Tag: TCT 2023
No difference in outcomes for AF patients undergoing LAAO and TAVI at the same time
Patients with atrial fibrillation (AF) undergoing a transcatheter aortic valve implantation (TAV...
TCT 2023: TAVI system for aortic regurgitation shows promise in ALIGN AR trial
Positive results from the ALIGN AR pivotal trial, investigating the use of the Trilogy (JenaValv...
TCT 2023: TRILUMINATE quality of life data point to benefit for patients with severe TR undergoing TEER
Analysis of health status and quality of life data from the TRILUMINATE Pivotal trial, presented...
TCT 2023: Initial phase of TRISCEND II trial of Evoque transcatheter replacement for severe tricuspid regurgitation meets primary endpoints
A randomised trial comparing transcatheter tricuspid valve replacement (TTVR) with the Evoque sy...
TCT 2023: Agent DCB shows superiority to conventional balloon angioplasty for target-lesion failure in US randomised trial
The first US randomised trial investigating the safety and efficacy on the use of a drug-coated ...
TCT 2023: Five-year PARTNER 3 results “reaffirm” role of TAVI as alternative to surgery in low-risk patients
Five-year data from the PARTNER 3 trial, which randomised low surgical risk aortic stenosis pati...
TCT 2023: LIFE-BTK breathes life into drug-eluting resorbable scaffolds in breakthrough for below-the-knee arteries
Results of the LIFE-BTK randomised controlled trial have just been presented at TCT 2023 (23–26 ...
TCT 2023: Intellistent multi-lumen stent system for pulmonary arterial hypertension wins Shark Tank innovation prize
HeartPoint Global was named winner in the Shark Tank Innovation Competition at the 2023 TCT conferen...
TCT 2023: First presentation of complete patient-level dataset on paclitaxel and death that helped sway the US FDA
Data from a patient-level meta-analysis—a factor in the US Food and Drug Administration’s (FDA) ...
